Last reviewed · How we verify

Keith Edwards, M.D. — Portfolio Competitive Intelligence Brief

Keith Edwards, M.D. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cladribine Tablets Cladribine Tablets marketed Purine nucleoside analog Ribonucleotide reductase; DNA incorporation Oncology; Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Haukeland University Hospital · 1 shared drug class
  2. M.D. Anderson Cancer Center · 1 shared drug class
  3. Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 1 shared drug class
  4. Nanfang Hospital, Southern Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Keith Edwards, M.D.:

Cite this brief

Drug Landscape (2026). Keith Edwards, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/keith-edwards-m-d. Accessed 2026-06-10.

Related